 Update on the diagnosis and management of systemic lupus erythematosus | |
| 主辦單位 | 社團法人高雄縣醫師公會 |
| 協辦單位 | 高雄市立鳳山醫院（委託財團法人長庚紀念醫院經營） |
| 上課日期時間 | 111年4月12日（星期二）12:30~14:30 |
| 課程地點 | 實體課程：高雄市立鳳山醫院（委託財團法人長庚紀念醫院經營）八樓會議室（高雄市鳳山區經武路42號） |
| 實體課程報名截止日期 | 2022/04/01 PM 16:59或額滿(80)為止 視訊課程免報名 |
| 講師 | 鄭添財／長庚醫療財團法人高雄長庚紀念醫院內科部風濕過敏免疫科 |
| 課程大綱 | Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it can be organ-dominant, posing diagnostic challenges. To date, diagnosis of SLE remains clinical with a few cases being negative for serologic tests. Diagnostic criteria are not available and classification criteria are often used for diagnosis, yet with significant caveats. Newer sets of criteria (European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019) enable earlier and more accurate classification of SLE. Several disease endotypes have been recognised over the years. There is increased recognition of milder cases at presentation, but almost half of them progress overtime to more severe disease. Approximately 70% of patients follow a relapsing-remitting course, the remaining divided equally between a prolonged remission and a persistently active disease. Treatment goals include long-term patient survival, prevention of flares and organ damage, and optimization of health-related quality of life. For organ-threatening or life-threatening SLE, treatment usually includes an initial period of high-intensity immunosuppressive therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate response and prevent relapses. Management of disease-related and treatment-related comorbidities, especially infections and atherosclerosis, is of paramount importance. New disease-modifying conventional and biologic agents—used alone, in combination or sequentially—have improved rates of achieving both short-term and long-term treatment goals, including minimisation of glucocorticoid use. Reference 1.2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus Ann Rheum Dis 2019;0:1151–1159 2.Update οn the diagnosis and management of systemic lupus erythematosus Ann Rheum Dis 2020;0:1–12. |
| 積分 | 西醫師繼續教育積分-專業課程、內科（僅限實體課程）、家醫科（僅限實體課程） |